VS
Venky Soundararajan
Nference (United States), Harvard Medical School, Massachusetts Institute of Technology, Indian Institute of Technology Guwahati
0000-0001-7434-9211
Employment
-
Nference (United States) Founder & Chief Scientific Officer2013 - Present
Education
-
Harvard Medical School Research Fellow2011 - 2012
-
Massachusetts Institute of Technology PhD2005 - 2010
-
Indian Institute of Technology Guwahati B.Tech.2001 - 2005
Projects & Funding
Projects & funding information is unavailable.
Publications (63)
- Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss Save
- Semaglutide and Tirzepatide in Type 1 Diabetes: Real-World Insulin Deintensification, Cardiovascular Outcomes and Safety Assessment Save
- Functional-vs-Cognitive Decline Heterogeneity in Alzheimer’s Disease Revealed by LLM-Curation of Decades of Clinical Notes has Implications for Semaglutide Trial Design Save
- Weight trajectories after last tirzepatide or semaglutide prescription across a federated health network Save
- Semaglutide use linked to lower COVID-19 and influenza severity with better renal outcomes after pandemic or seasonal infection Save
- GLP-1–based incretin therapy is associated with lower incident Alzheimer’s disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk Save
- Decoding the hallmarks of GLP-1RA weight-loss super-responders Save
- Auditable large language model curation of clinical notes refines glucagon-like peptide-1 initiation, persistence ascertainment, and compounding use beyond prescription records Save
- Weight trajectories after last Tirzepatide or Semaglutide prescription across a federated health network Save
- Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping Save